Tumor size and effectiveness of electrochemotherapy

1. Marty M, Sersa G, Garbay JR, Gehl J, Collins CG, Snoj M, et al. Electrochemotherapy - An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. Eur J Cancer Suppl 2006; 4: 3-13.10.1016/j.ejcsup.2006.08.002Search in Google Scholar

2. Sersa G, Miklavcic D, Cemazar M, Rudolf Z, Pucihar G, Snoj M. Electrochemotherapy in treatment of tumours. Eur J Surg Oncol 2008; 34: 232-240.10.1016/j.ejso.2007.05.01617614247Search in Google Scholar

3. Snoj M, Rudolf Z, Cemazar M, Jancar B, Sersa G. Successful sphincter-saving treatment of anorectal malignant melanoma with electrochemotherapy, local excision and adjuvant brachytherapy. Anticancer Drugs 2005; 16: 345-348.10.1097/00001813-200503000-0001515711188Search in Google Scholar

4. Snoj M, Cemazar M, Srnovrsnik T, Paulin-Kosir SM, Sersa G. Limb sparing treatment of bleeding melanoma recurrence by electrochemotherapy. Tumori 2009; 95: 398-402.10.1177/030089160909500324Search in Google Scholar

5. Colombo GL, Di Matteo S, Mir LM. Cost-effectiveness analysis of electrochemotherapy with the CliniporatorTM vs other methods for the control and treatment of cutaneous and subcutaneous tumors. Ther Clin Risk Manag 2008; 4: 541-548.10.2147/TCRM.S2780250405218728828Search in Google Scholar

6. Moller MG, Salwa S, Soden DM, O’Sullivan GC. Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma. Expert Rev Anticancer Ther 2009; 9: 1611-1630.10.1586/era.09.12919895245Search in Google Scholar

7. Testori A, Faries MB, Thompson JF, Pennacchioli E, Deroose JP, van Geel AN, et al. Local and intralesional therapy of in-transit melanoma metastases. JSurg Oncol 2011; 104: 391-396.10.1002/jso.2202921858834Search in Google Scholar

8. Mir LM, Gehl J, Sersa G, Collins CG, Garbay JR, Billard V, et al. Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or noninvasive electrodes. Eur J Cancer Suppl 2006; 4: 14-25.10.1016/j.ejcsup.2006.08.003Search in Google Scholar

9. Campana LG, Mocellin S, Basso M, Puccetti O, De Salvo GL, Chiarion-Sileni V, et al. Bleomycin-based electrochemotherapy: clinical outcome from a single institution’s experience with 52 patients. Ann Surg Oncol 2009; 16: 191-199.10.1245/s10434-008-0204-818987914Search in Google Scholar

10. Curatolo P, Quaglino P, Marenco F, Mancini M, Nardo T, Mortera C, et al. Electrochemotherapy in the treatment of Kaposi sarcoma cutaneous lesions: a two-center prospective phase II trial. Ann Surg Oncol 2012; 19: 192-198.10.1245/s10434-011-1860-721822561Search in Google Scholar

11. Quaglino P, Mortera C, Osella-Abate S, Barberis M, Illengo M, Rissone M, et al. Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann Surg Oncol 2008; 15: 2215-2222.10.1245/s10434-008-9976-018498012Search in Google Scholar

12. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.10.1136/bmj.b2700271467219622552Search in Google Scholar

13. Wieseler B, McGauran N. Reporting a systematic review. Chest 2010; 137: 1240-1246.10.1378/chest.09-262520442127Search in Google Scholar

14. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. UK: Wiley-Blackwell; 2008.10.1002/9780470712184Search in Google Scholar

15. World Health Organization. WHO handbook for reporting results of cancertreatment. Switzerland: World Health Organization; 1979.Search in Google Scholar

16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.10.1093/jnci/92.3.20510655437Search in Google Scholar

17. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to metaanalysis. UK: Wiley; 2009.10.1002/9780470743386Search in Google Scholar

18. Byrne CM, Thompson JF, Johnston H, Hersey P, Quinn MJ, Hughes TM, et al. Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res 2005; 15: 45-51.10.1097/00008390-200502000-0000815714120Search in Google Scholar

19. Landstrom FJ, Nilsson COS, Crafoord S, Reizenstein JA, Adamsson GBM, Lofgren LA. Electroporation therapy of skin cancer in the head and neck area. Dermatol Surg 2010; 36: 1245-1250.10.1111/j.1524-4725.2010.01617.x20666812Search in Google Scholar

20. Larkin JO, Collins CG, Aarons S, Tangney M, Whelan M, O’Reily S, et al. Electrochemotherapy - Aspects of preclinical development and early clinical experience. Ann Surg 2007; 245: 469-479.10.1097/01.sla.0000250419.36053.33187702717435555Search in Google Scholar

21. Matthiessen LW, Chalmers RL, Sainsbury DCG, Veeramani S, Kessell G, Humphreys AC, et al. Management of cutaneous metastases using electrochemotherapy. Acta Oncol 2011; 50: 621-629.10.3109/0284186X.2011.573626313099721574833Search in Google Scholar

22. Rols MP, Bachaud JM, Giraud P, Chevreau C, Roche H, Teissie J. Electrochemotherapy of cutaneous metastases in malignant melanoma. Melanoma Res 2000; 10: 468-474.10.1097/00008390-200010000-00009Search in Google Scholar

23. Domenge C, Orlowski S, Luboinski B, DeBaere T, Schwaab G, Belehradek J, et al. Antitumor electrochemotherapy - New advances in the clinical protocol. Cancer 1996; 77: 956-963.10.1002/(SICI)1097-0142(19960301)77:5<956::AID-CNCR23>3.0.CO;2-1Search in Google Scholar

24. Miklavcic D, Beravs K, Semrov D, Cemazar M, Demsar F, Sersa G. The importance of electric field distribution for effective in vivo electroporation of tissues. Biophys J 1998; 74: 2152-2158.10.1016/S0006-3495(98)77924-XSearch in Google Scholar

25. Miklavcic D, Corovic S, Pucihar G, Pavselj N. Importance of tumour coverage by sufficiently high local electric field for effective electrochemotherapy. EurJ Cancer Suppl 2006; 4: 45-51.10.1016/j.ejcsup.2006.08.006Search in Google Scholar

26. Miklavcic D, Towhidi L. Numerical study of the electroporation pulse shape effect on molecular uptake of biological cells. Radiol Oncol 2010; 44: 34-41.10.2478/v10019-010-0002-3Search in Google Scholar

27. Cemazar M, Milacic R, Miklavcic D, Dolzan V, Sersa G. Intratumoral cisplatin administration in electrochemotherapy: antitumor effectiveness, sequence dependence and platinum content. Anticancer Drugs 1998; 9: 525-530.10.1097/00001813-199807000-00002Search in Google Scholar

28. Front D, Israel O, Iosilevsky G, Even-Sapir E, Ben-Haim S, Frenkel A, et al. Administered dose and tumor dose of bleomycin labeled with cobalt-57 in mice and men. J Nucl Med 1990; 31: 1784-1790.Search in Google Scholar

29. Mir LM, Tounekti O, Orlowski S. Bleomycin: Revival of an old drug. GenPharmac 1996; 27: 745-748.10.1016/0306-3623(95)02101-9Search in Google Scholar

30. Hall SW, Strong JE, Broughton A, Frazier ML, Benjamin RS. Bleomycin clinical pharmacology by radioimmunoassay. Cancer Chemother Pharmacol 1982; 9: 22-25.10.1007/BF00296756Search in Google Scholar

31. Alberts DS, Chen HS, Liu R, Himmelstein KJ, Mayersohn M, Perrier D, et al. Bleomycin pharmacokinetics in man. I. Intravenous administration. CancerChemother Pharmacol 1978; 1: 177-181.Search in Google Scholar

32. Sersa G, Jarm T, Kotnik T, Coer A, Podkrajsek M, Sentjurc M, et al. Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma. Br J Cancer 2008; 98: 388-398.10.1038/sj.bjc.6604168Search in Google Scholar

33. Sersa G, Krzic M, Sentjurc M, Ivanusa T, Beravs K, Kotnik V, et al. Reduced blood flow and oxygenation in SA-1 tumours after electrochemotherapy with cisplatin. Br J Cancer 2002; 87: 1047-1054.10.1038/sj.bjc.6600606Search in Google Scholar

34. Sersa G, Cemazar M, Miklavcic D. Tumor blood flow modifying effects of electrochemotherapy: a potential vascular targeted mechanism. RadiolOncol 2003; 37: 43-48.Search in Google Scholar

35. Jarm T, Cemazar M, Miklavcic D, Sersa G. Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases. ExpertRev Anticancer Ther 2010; 10: 729-746.10.1586/era.10.4320470005Search in Google Scholar

36. Miklavcic D, Snoj M, Zupanic A, Kos B, Cemazar M, Kropivnik M, et al. Towards treatment planning and treatment of deep-seated solid tumors by electrochemotherapy. BioMed Eng OnLine 2010; 9: 10.10.1186/1475-925X-9-10284368420178589Search in Google Scholar

37. Edhemovic I, Gadzijev EM, Brecelj E, MIklavcic M, Kos B, Zupanic A, et al. Electrochemotherapy: a new technological approach in treatment of metastases in the liver. Technol Cancer Res Treat 2011; 10: 475-485.10.7785/tcrt.2012.500224452741421895032Search in Google Scholar

38. Pavliha D, Kos B, Zupanic A, Marcan M, Sersa G, Miklavcic D. Patient-specific treatment planning of electrochemotherapy: Procedure design and possible pitfalls. Bioelectrochemistry 2012; 87: 265-273.10.1016/j.bioelechem.2012.01.00722341626Search in Google Scholar

39. Adeyanju OO, Al-Angari HM, Sahakian AV. The optimization of needle electrode number and placement for irreversible electroporation of hepatocellular carcinoma. Radiol Oncol 2012; 46: 126-135.10.2478/v10019-012-0026-y347294023077449Search in Google Scholar